Quick Answer
CRESCENT BIOPHARMA, INC. reported R&D Expense of $138.09 million for fiscal year 2025.
CRESCENT BIOPHARMA, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $138.09M | +868.4% |
| 2024 | $14.26M | -29.0% |
| 2023 | $20.07M | -29.3% |
| 2022 | $28.39M | -40.2% |
| 2021 | $47.49M | +5.7% |
| 2020 | $44.93M | -4.5% |
| 2019 | $47.03M | +17.3% |
| 2018 | $40.09M | +66.4% |
| 2017 | $24.10M | +3.5% |
| 2016 | $23.28M | -7.1% |
| 2015 | $25.05M | +28.0% |
| 2014 | $19.57M | +67.3% |
| 2013 | $11.70M | +24.0% |
| 2012 | $9.44M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $20.35M | +722.8% | +68.4% |
| June 30, 2025 | $12.08M | +92.2% | +81661.0% |
| March 31, 2025 | $14.8K | -99.8% | -99.4% |
| September 30, 2024 | $2.47M | -53.3% | -60.7% |
| June 30, 2024 | $6.29M | +54.3% | +4.3% |
| March 31, 2024 | $6.03M | +11.2% | +13.9% |
| September 30, 2023 | $5.29M | +7.5% | +29.9% |
| June 30, 2023 | $4.07M | -48.9% | -24.8% |
- CRESCENT BIOPHARMA, INC. showed an increase of +868.4% in R&D Expense compared to the prior fiscal year.
- Over the 2012–2025 period, CRESCENT BIOPHARMA, INC.’s r&d expense has grown by 1363.0% (from $9.44 million to $138.09 million).
- The most recent figure is from CRESCENT BIOPHARMA, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: